tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data
PremiumRatingsAnalyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data
2M ago
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
Premium
Ratings
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
2M ago
Caribou Biosciences presents ANTLER trial results at EHA
Premium
The Fly
Caribou Biosciences presents ANTLER trial results at EHA
2M ago
Caribou CB-011 granted Regenerative Medicine Advanced Therapy designation
PremiumThe FlyCaribou CB-011 granted Regenerative Medicine Advanced Therapy designation
5M ago
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
Premium
The Fly
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
5M ago
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
Premium
Ratings
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
5M ago
Caribou Biosciences price target lowered to $6 from $8 at BofA
PremiumThe FlyCaribou Biosciences price target lowered to $6 from $8 at BofA
7M ago
Caribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating
Premium
Ratings
Caribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating
9M ago
Caribou Biosciences Reports Increased Losses Amid R&D Focus
Premium
Company Announcements
Caribou Biosciences Reports Increased Losses Amid R&D Focus
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100